Form 4: Zoetis EVP Julie Fuller Receives Equity Awards

Zoetis Inc. Executive Vice President Julie Fuller was granted restricted stock units and stock options under the company's equity incentive plan.

Summary

• Executive Vice President Julie Fuller received new equity awards from Zoetis Inc.
• Awards include 3,626 Restricted Stock Units (RSUs) and 14,345 stock options, both granted on February 18, 2026.
• The RSUs represent a contingent right to receive one share of common stock each, with vesting occurring in one-third increments on the first, second, and third anniversaries of the grant date (February 18, 2026).
• The stock options have an exercise price of $129.13 and also vest in one-third increments on the first, second, and third anniversaries of the grant date (February 18, 2026), expiring on the tenth anniversary of the grant date.
• The filing also reports previously granted RSUs (2,250.4257 units from February 19, 2025, and 1,580.2077 units from September 30, 2024) and stock options (8,642 units from February 19, 2025, with an exercise price of $156.64), all with similar three-year vesting schedules.
• All awards are granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any significant operational or financial changes.

Positives

• Equity awards align management's interests with those of shareholders, incentivizing long-term performance.
• The multi-year vesting schedules promote executive retention over several years.

Negatives

• The issuance of new equity awards can lead to minor share dilution, though this is a standard component of executive compensation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity-based compensation, such as restricted stock units and stock options, is a prevalent practice across the pharmaceutical and animal health industries. This approach is widely used to attract, retain, and motivate key executives by linking their personal financial success to the long-term performance of the company.

Comparison to Industry Standards

• Executive compensation packages in the animal health sector, including companies like Elanco Animal Health (ELAN) and IDEXX Laboratories (IDXX), commonly feature a significant portion of equity awards.
• The structure of Zoetis's grants, with multi-year vesting, aligns with best practices aimed at fostering long-term value creation and executive retention, similar to programs seen at major pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution from new equity awards, but also increased alignment of executive incentives with long-term shareholder value.
• Employees: Standard executive compensation practices may signal stability in leadership.

Next Steps

• Vesting of 3,626 Restricted Stock Units on the first, second, and third anniversaries of February 18, 2026.
• Vesting of 14,345 Stock Options on the first, second, and third anniversaries of February 18, 2026.
• Continued vesting of previously granted RSUs and stock options according to their respective schedules.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for an executive and does not contain information that would typically warrant a change in investment recommendation. It primarily serves as a transparency disclosure of insider holdings and incentives.

Keywords

Zoetis, ZTS, Julie Fuller, Executive Compensation, Restricted Stock Units, Stock Options, Insider Transaction, Equity Incentive Plan, SEC Form 4